Advancing synthetic therapies for the treatment of restless legs syndrome

References

• Anguelova GV, Vlak MHM, Kurvers AGY, et al. Pharmacologic and nonpharmacologic treatment of restless legs syndrome. Sleep Med Clin. 2018;13:219–230.
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–65.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–295.
   PubMed Web of Science ®Google Scholar
• Bassetti C, Mauerhofer D, Gugger M, et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol. 2001;45:67–74.
   PubMed Web of Science ®Google Scholar
• Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54:1698–1700.
   PubMed Web of Science ®Google Scholar
• Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med. 2004;5:309–315.
   PubMed Web of Science ®Google Scholar
• Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep. 2007;30:866–871.
   PubMed Web of Science ®Google Scholar
• Manconi M, Ferini-Strambi L, Filippi M, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep. 2008;31:944–952.
   PubMed Web of Science ®Google Scholar
• Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63:1065–1069.
   PubMed Web of Science ®Google Scholar
• O’Keeffe ST. Secondary causes of restless legs syndrome in older people. Age Ageing. 2005;34:349–352.
   PubMed Web of Science ®Google Scholar
• Ferré S, García-Borreguero D, Allen RP, et al. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25:113–125.
   PubMed Web of Science ®Google Scholar
• Schormair B, Winkelmann J. Genetics of restless legs syndrome: mendelian, complex, and everything in between. Sleep Med Clin. 2011;6:203–215.
   Google Scholar
• Schormair B, Zhao C, Bell S, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol. 2017;16:898–907.
   PubMed Web of Science ®Google Scholar
• Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol. 2004;115:1965–1974.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Latapi P, Malkani R. Update on restless legs syndrome: from mechanisms to treatment. Curr Neurol Neurosci Rep. 2019;19:54.
   PubMed Web of Science ®Google Scholar
• Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9:776–790.
   PubMed Web of Science ®Google Scholar
• Silber MH, Becker PM, Earley C, et al. Medical advisory board of the Willis-Ekbom disease foundation. Willis-Ekbom disease foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–986.
   PubMed Web of Science ®Google Scholar
• Kwatra V, Khan MA, Quadri SA, et al. Differential diagnosis and treatment of restless legs syndrome: a literature review. Cureus. 2018;10:e3297.
   PubMed Web of Science ®Google Scholar
• Ghorayeb I. Idiopathic restless legs syndrome treatment: progress and pitfalls? Adv Pharmacol. 2019;84:207–235.
   PubMedGoogle Scholar
• de Biase S, Valente M, Gigli GL. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. Neuropsychiatr Dis Treat. 2016;12:417–425.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International restless legs syndrome study group consensus conference at the max planck institute. Sleep Med. 2007;8:520–530.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep Med. 2004;5:5–6.
   PubMed Web of Science ®Google Scholar
• de Biase S, Merlino G, Valente M, et al. Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12:1035–1045.
   PubMed Web of Science ®Google Scholar
• LYRICA: prescribing information. cited 2019 Apr 20]. Available from: http://www.lyrica.com/
   Google Scholar
• Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37:635–643.
   PubMed Web of Science ®Google Scholar
• Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–631.
   PubMed Web of Science ®Google Scholar
• Allen RP, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11:512–519.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults. Neurology. 2016;87:2585–2593.
   PubMed Web of Science ®Google Scholar
• Quintero GC. Review about gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol. 2017;9:13–21.
   PubMedGoogle Scholar
• Razazian N, Azimi H, Heidarnejadian J, et al. Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. Saudi J Kidney Dis Transpl. 2015;26:271–278.
   PubMed Web of Science ®Google Scholar
• Saletu M, Anderer P, Saletu-Zyhlarz GM, et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm. 2010;117:463–473.
   PubMed Web of Science ®Google Scholar
• Guttuso T, Shaman M, Thornburg L. Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;181:280–283.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Annamalai T, Bu L, et al. XP13512 [(±)-1-([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol ExpTher. 2004;311:324–333.
   PubMed Web of Science ®Google Scholar
• Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72:439–446.
   PubMed Web of Science ®Google Scholar
• Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282–292.
   PubMed Web of Science ®Google Scholar
• Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo- controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165–173.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Hays R, Steven Poceta J, et al. Effect of gabapentin enacarbil on individual items of the international restless legs study group rating scale and post-sleep questionnaire in adults with moderate-to-severe primary restless legs syndrome: pooled analysis of 3 randomized trials. Clin Ther. 2016;38:1726–1737.
   PubMed Web of Science ®Google Scholar
• Avidan AY, Lee D, Park M, et al. The effect of gabapentin enacarbil on quality of life and mood outcomes in a pooled population of adult patients with moderate-to-severe primary restless legs syndrome. CNS Drugs. 2016;30:305–316.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hermanowicz N, Borreguero DG, et al. Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials. J Clin Mov Disord. 2015;30(2):9.
   Google Scholar
• Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34:8–16.
   PubMed Web of Science ®Google Scholar
• Blinded, randomized study of gabapentin (neurontin®) and gabapentin enacarbil (horizant™) in restless leg syndrome. NCT02117076 [cited 2019 Apr 20]. Available from: http://clinicaltrials.gov/
   Google Scholar
• MIRAPEX: prescribing information. [cited 2019 Apr 20]. Available from: http://www.mirapex.com/
   Google Scholar
• Inoue Y, Kuroda K, Hirata K, et al. Long-term open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci. 2010;294:62–66.
   PubMed Web of Science ®Google Scholar
• Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of pramipexole in patients with restless legs syndrome (extension of the PRELUDE study). Sleep Med. 2008;9:537–541.
   PubMed Web of Science ®Google Scholar
• Bassetti CL, Bornatico F, Fuhr P, et al. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly. 2011;141:w13274.
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002;3:23–25.
   PubMed Web of Science ®Google Scholar
• Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–444.
   PubMed Web of Science ®Google Scholar
• Maestri M, Fulda S, Ferini-Strambi L, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2014;15:570–575.
   PubMed Web of Science ®Google Scholar
• REQUIP: prescribing information. [cited 2019 Apr 20]. Available from: http://www.gsksource.com/
   Google Scholar
• Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther. 2013;35:1321–1336.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67:1034–1039.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Högl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277–283.
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Cawello W, Andreas JO, et al. An update on pharmacological, pharmacokinetic properties and drug–drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75:487–501.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med. 2013;14:1085–1091.
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Beneš H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–720.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Canelo M, Lang M, et al. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017;30:257–265.
   PubMed Web of Science ®Google Scholar
• Benes H, Garcia-Borreguero D, Allen R, et al. Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine - a retrospective systematic analysis of two large open label1-year trials. Mov Disord. 2009;24(Suppl 1):438.
   Google Scholar
• Zhou W, Lv C, Zhang Q, et al. Pharmacokinetics, pharmacodynamics, and safety of rasagiline transdermal patch: a preliminary study in healthy Chinese subjects. Clin Drug Investig. 2018;38:125–133.
   PubMed Web of Science ®Google Scholar
• Babacan-Yildiz G, Gursoy E, Kolukisa M, et al. Restless legs syndrome responsive to rasagiline treatment: a case report. Clin Neuropharmacol. 2012;35:88–89.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Grogan P. A tale of two restless sisters. Neurology. 2013;80(Supplement 7):P02.067.
   Google Scholar
• Safety and efficacy of rasagiline in restless legs syndrome. NCT01192503. [cited 2019 Apr 20]. Available from: http://clinicaltrials.gov/
   Google Scholar
• AZILECT: prescribing information. [cited 2019 Apr 20]. Available from: http://www.azilect.com/
   Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet. 2002;41:261–309.
   PubMed Web of Science ®Google Scholar
• Earley CJ, Allen RP. Augmentation of the restless legs syndrome with carbidopa-levodopa. Sleep. 1996;19:801–810.
   PubMed Web of Science ®Google Scholar
• TARGIN: product monograph. [cited 2019 Apr 20]. Available from: http://www.purdue.ca/
   Google Scholar
• Sun YM, Hoang T, Neubauer JA, et al. Opioids protect against substantia nigra cell degeneration under conditions of iron deprivation: a mechanism of possible relevance to the Restless Legs Syndrome (RLS) and Parkinson’s disease. J Neurol Sci. 2011;304:93–101.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Beneš H, Grote L. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–1150.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Hallström Y, Saletu-Zyhlarz GM. Sleep and quality of life under prolonged release oxycodone/naloxone for severe restless legs syndrome: an analysis of secondary efficacy variables of a double-blind, randomized, placebo-controlled study with an open-label extension. CNS Drugs. 2016;30:749–760.
   PubMed Web of Science ®Google Scholar
• TOPAMAX: product information. [cited 2019 Apr 20]. Available from: http://www.topamax.com/
   Google Scholar
• Pérez A. Topiramate use as treatment in restless legs syndrome. Actas Esp Psiquiatr. 2004;32:132–137.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of topiramate to treat restless legs syndrome. NCT0020941. [cited 2019 Apr 20]. Available from: http://clinicaltrials.gov/
   Google Scholar
• Korkmaz S, Aksu M. Topiramate induced restless legs syndrome: case report. J Turk Sleep Med. 2014;1:36–37.
   Google Scholar
• WELLBUTRIN: Prescribing Information. cited 2019 Apr 20]. Available from: http://www.gsksource.com/
   Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol. 2005;28:298–301.
   PubMed Web of Science ®Google Scholar
• Bayard M, Bailey B, Acharya D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011;24:422–428.
   PubMed Web of Science ®Google Scholar
• Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome. Sleep. 1998;21:371–377.
   PubMed Web of Science ®Google Scholar
• Trotti LM. Restless legs syndrome and sleep-related movement disorders. Continuum (Minneap Minn). 2017;23:1005–1016.
   PubMedGoogle Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International restless legs syndrome study group. Sleep Med. 2013;14:675–684.
   PubMed Web of Science ®Google Scholar
• Trotti LM, Becker LA. Iron for the treatment of restless legs syndrome. Cochrane Database Syst Rev. 2019;1:CD007834.
   PubMedGoogle Scholar
• Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27–44.
   PubMed Web of Science ®Google Scholar
• de Biase S, Merlino G, Lorenzut S, et al. ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol. 2012;8:1247–1261.
   PubMed Web of Science ®Google Scholar
• Ibia M, Sawadab H, Nakanishia M, et al. Protective effects of 1,25- (OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacol. 2001;40:761–771.
   PubMed Web of Science ®Google Scholar
• Wali S, Alsafadi S, Abaalkhail B, et al. The association between vitamin D level and restless legs syndrome: a population-based case-control study. J Clin Sleep Med. 2018;14:557–564.
   PubMed Web of Science ®Google Scholar
• Wali S, Shukr A, Boudal A, et al. The effect of vitamin D supplements on the severity of restless legs syndrome. Sleep Breath. 2015;19:579–583.
   PubMed Web of Science ®Google Scholar
• Cholecalciferol supplementation in Restless Leg Syndrome in patients with chronic kidney disease (RLS). NCT03063190. [cited 2019 Apr 20]. Available from: http://clinicaltrials.gov/
   Google Scholar
• Wijemanne S, Ondo W. Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management. Pract Neurol. 2017;17:444–452.
   PubMedGoogle Scholar
• de Biase S, Merlino G, Lorenzut S, et al. ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. Expert Opin Drug Metab Toxicol. 2014;10:1365–1380.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Latapi P, Malkani R. Update on restless legs syndrome: from mechanism to treatment. Curr Neurol Neurosci Rep. 2019;19:54.
   PubMed Web of Science ®Google Scholar
• Zucconi M, Galbiati A, Rinaldi F, et al. An update on the treatment of restless legs syndrome/willis-ekbom disease: prospects and challenges. Expert Rev Neurother. 2018;18: 705–713.
   PubMed Web of Science ®Google Scholar
• de Biase S, Merlino G, Lorenzut S, et al. Investigational approaches to therapies for restless legs syndrome. Expert Opin Invest Drugs. 2014;23:847–856.
   PubMed Web of Science ®Google Scholar
• Högl B, Comella C. Therapeutic advances in restless legs syndrome (RLS). Mov Disord. 2015;30:1574–1579.
   PubMed Web of Science ®Google Scholar